ClinicalTrials.gg
CompletedNCT02985541METUpdated Apr 28, 2022Results posted

Mirena Extension Trial

A Phase 3 interventional study of Levonorgestrel IUS (Mirena, BAY86-5028) in Contraception, sponsored by Bayer. Completed at 49 sites in United States. Open to female participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2022-04-28.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
364
Allocation
Not applicable
Ages
18 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Menorrhagia by Bayer — none open to participants now, none under way, none of them phase 3. Menorrhagia · Bayer.

Started
2016
the only one that year
Phase 3
6 of 19
none open now
Registered
14th of 19
by date

Among the 19 studies in Menorrhagia by Bayer, this one is the only one that started in 2016, is one of 6 in phase 3, and was the 14th registered.

Menorrhagia

206 studies on the registry are indexed under Menorrhagia; 35 are open to participants now.

Browse Menorrhagia studies →

Open to participants now

None of the 19 studies in Menorrhagia by Bayer is open now. The open studies under Menorrhagia, anywhere →

Who these studies take

Of the 23 Menorrhagia studies recruiting now, 4 (17%) set no upper age limit and 19 (83%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 35 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Menorrhagia by Bayer as a file.
02

Study summary

The study is performed to assess if Mirena is effective and safe as a birth control method beyond 5 years of use. Further the menstrual blood loss (in women that had Mirena inserted for the indication heavy menstrual bleeding [HMB]) and safety will be assessed.

03

Conditions studied

  • Contraception

Browse trials for

Keywords

  • Birth Control
  • Heavy menstrual bleeding
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated
  • Women, 18 to 35 years of age at the time of screening (visit 1) who are currently using Mirena for or for contraception and heavy menstrual bleeding. The duration of use of the current Mirena has to be at least 4 years 6 months at the start of screening phase but not more than 5 years at visit 2 and the woman is willing to continue with its use and has a continuing need for contraception.
  • Normal or clinically insignificant cervical smear not requiring further follow up

Exclusion criteria

Exclusion Criteria:

  • Menopausal symptoms with Follicle-stimulating hormone>30 mIU/ml
  • Pregnancy or suspicion of pregnancy
  • Uterine bleeding of unknown etiology
  • Untreated acute cervicitis or vaginitis or other lower genital tract infections
  • Increased susceptibility to pelvic infection
  • Acute pelvic inflammatory disease (PID) or a history of PID unless successfully treated and which, in the investigator's opinion, has not negatively affected subject's fertility
  • Congenital or acquired uterine anomaly if it distorts the uterine cavity
  • History of, diagnosed or suspected genital or other and untreated cervical dysplasia
  • Any active acute liver disease or liver tumor (benign or malignant)
  • endometrial polyp(s)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
364 participants (actual)

Study arms

  • Experimental
    Levonorgestrel IUS (Mirena, BAY86-5028)

    Mirena during extended use (Years 6 to 8).

    Drug: Levonorgestrel IUS (Mirena, BAY86-5028)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Pregnancies Per 100 Women Years (Pearl Index [PI]) Within Years 6 Thru 8 of Mirena Use

    The Pearl Index (PI) is defined as the number of pregnancies per 100 women years. The 3-year PI (Years 6 to 8) was obtained by dividing the number of pregnancies the occurred during that time (starting at Day 1 Year 6 and up to Day 365 of Year 8) by the time (in 100 women years) that the women were at risk of getting pregnant during that time.

    Time frame: Years 6 to 8 of Mirena use

Secondary outcomes

  1. Menstrual Blood Loss (MBL) During a 30-day Period Starting at the Baseline Visit and at the End of Years 6, 7 and 8

    Menstrual blood loss (MBL) during a 30-day period starting at the baseline visit and at the end of Year 6, Year 7, and Year 8, measured by the alkaline hematin method. The assessment of this variable was restricted to women who had Mirena inserted for heavy menstrual bleeding (HMB).

    Time frame: Baseline and end of Years 6, 7 and 8 of Mirena use

  2. Number of Participants With Menstrual Blood Loss (MBL) (>= 80 ml Per 30 Days) at End of Year 6, 7 and 8 of Mirena Use

    Categorized menstrual blood loss (MBL) (≥ 80 mL per 30 days) at end of Year 6, Year 7, and Year 8. The assessment of this variable was restricted to women who had Mirena inserted for HMB.

    Time frame: At end of Year 6, 7 and 8 of Mirena use

  3. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Adverse event (AE) was defined as any untoward medical occurrence (ie any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a patient or clinical investigation subject after providing written informed consent for participation in the study. Serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose 1) resulted in death, 2) was life-threatening, 3) required inpatient hospitalization or prolongation of existing hospitalization, 4) resulted in persistent or significant disability/incapacity, 5) was a congenital anomaly/birth defect, or 6) was another medically important serious event as judged by the investigator. Treatment-emergent adverse event (TEAE) was defined as an AE that occurred on Day 1 Year 6 of Mirena use or later.

    Time frame: Years 6 to 8 of Mirena use

Other outcomes

  1. Total LNG Concentrations in Plasma Estimated Based on the Final 8-year Population Pharmacokinetics (popPK) Model

    A population pharmacokinetic (popPK) analysis was performed including sparse data from the study.

    Time frame: At the beginning of Year 6 (baseline) and at the end of Years 6, 7, and 8 of Mirena use

  2. Participant's Satisfaction With Mirena by Visit

    Participants were asked to evaluate their satisfaction with Mirena on a 5-point scale as very satisfied, somewhat satisfied, neither satisfied or dissatisfied, dissatisfied or very dissatisfied.

    Time frame: Baseline, at end of Year 6, 7 and 8 of Mirena use

07

Results

Posted Apr 28, 2022

Participant flow

Participant flow — Overall Study
MilestoneLevonorgestrel IUS (Mirena, BAY86-5028)
Started364
Valid for fas362
Continued into year 7 of mirena use305
Continued into year 8 of mirena use243
Completed223
Not completed141
Withdrew: Withdrawal by subject33
Withdrew: Lost to follow-up26
Withdrew: Adverse event27
Withdrew: Physician decision2
Withdrew: Pregnancy2
Withdrew: Wish for pregnancy44
Withdrew: Other reason5
Withdrew: Not valid for analysis2

Outcome measures

PrimaryNumber of Pregnancies Per 100 Women Years (Pearl Index [PI]) Within Years 6 Thru 8 of Mirena Use

The Pearl Index (PI) is defined as the number of pregnancies per 100 women years. The 3-year PI (Years 6 to 8) was obtained by dividing the number of pregnancies the occurred during that time (starting at Day 1 Year 6 and up to Day 365 of Year 8) by the time (in 100 women years) that the women were at risk of getting pregnant during that time.

Time frame:
Years 6 to 8 of Mirena use
Reported as:
Number · Pregnancies per 100 women years
Number of Pregnancies Per 100 Women Years (Pearl Index [PI]) Within Years 6 Thru 8 of Mirena Use
Pregnancies per 100 women yearsLevonorgestrel IUS (Mirena, BAY86-5028)
Number of Pregnancies Per 100 Women Years (Pearl Index [PI]) Within Years 6 Thru 8 of Mirena Use0.28 (0.03 to 1.00)
Statistical analysis
  • Levonorgestrel IUS (Mirena, BAY86-5028) · 3-year probability of getting pregnant: 0.68 · 95% CI 0.17 to 2.71
SecondaryMenstrual Blood Loss (MBL) During a 30-day Period Starting at the Baseline Visit and at the End of Years 6, 7 and 8

Menstrual blood loss (MBL) during a 30-day period starting at the baseline visit and at the end of Year 6, Year 7, and Year 8, measured by the alkaline hematin method. The assessment of this variable was restricted to women who had Mirena inserted for heavy menstrual bleeding (HMB).

Time frame:
Baseline and end of Years 6, 7 and 8 of Mirena use
Reported as:
Median · mL/30 days
Menstrual Blood Loss (MBL) During a 30-day Period Starting at the Baseline Visit and at the End of Years 6, 7 and 8
mL/30 daysLevonorgestrel IUS (Mirena, BAY86-5028)
Beginning of Year 6 (baseline)0.000 (0.00 to 2.32)
End of Year 60.000 (0.00 to 0.00)
End of Year 70.000 (0.00 to 0.00)
End of Year 80.000 (0.00 to 0.00)
SecondaryNumber of Participants With Menstrual Blood Loss (MBL) (>= 80 ml Per 30 Days) at End of Year 6, 7 and 8 of Mirena Use

Categorized menstrual blood loss (MBL) (≥ 80 mL per 30 days) at end of Year 6, Year 7, and Year 8. The assessment of this variable was restricted to women who had Mirena inserted for HMB.

Time frame:
At end of Year 6, 7 and 8 of Mirena use
Reported as:
Number · Participants
Number of Participants With Menstrual Blood Loss (MBL) (>= 80 ml Per 30 Days) at End of Year 6, 7 and 8 of Mirena Use
ParticipantsLevonorgestrel IUS (Mirena, BAY86-5028)
End of Year 60
End of Year 70
End of Year 80
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

Adverse event (AE) was defined as any untoward medical occurrence (ie any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a patient or clinical investigation subject after providing written informed consent for participation in the study. Serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose 1) resulted in death, 2) was life-threatening, 3) required inpatient hospitalization or prolongation of existing hospitalization, 4) resulted in persistent or significant disability/incapacity, 5) was a congenital anomaly/birth defect, or 6) was another medically important serious event as judged by the investigator. Treatment-emergent adverse event (TEAE) was defined as an AE that occurred on Day 1 Year 6 of Mirena use or later.

Time frame:
Years 6 to 8 of Mirena use
Reported as:
Number · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsLevonorgestrel IUS (Mirena, BAY86-5028)
Any AE249
Any SAE14
Other pre-specifiedTotal LNG Concentrations in Plasma Estimated Based on the Final 8-year Population Pharmacokinetics (popPK) Model

A population pharmacokinetic (popPK) analysis was performed including sparse data from the study.

Time frame:
At the beginning of Year 6 (baseline) and at the end of Years 6, 7, and 8 of Mirena use
Reported as:
Geometric mean · ng/L
Total LNG Concentrations in Plasma Estimated Based on the Final 8-year Population Pharmacokinetics (popPK) Model
ng/LLevonorgestrel IUS (Mirena, BAY86-5028)
At the beginning of Year 6 (baseline)123 ± 38.3
At the end of Year 6114 ± 38.7
At the end of Year 7106 ± 39.2
At the end of Year 8100 ± 39.9
Other pre-specifiedParticipant's Satisfaction With Mirena by Visit

Participants were asked to evaluate their satisfaction with Mirena on a 5-point scale as very satisfied, somewhat satisfied, neither satisfied or dissatisfied, dissatisfied or very dissatisfied.

Time frame:
Baseline, at end of Year 6, 7 and 8 of Mirena use
Reported as:
Number · Participants
Participant's Satisfaction With Mirena by Visit
ParticipantsLevonorgestrel IUS (Mirena, BAY86-5028)
Baseline (very satisfied)342
Baseline (somewhat satisfied)20
Baseline (neither satisfied nor dissatisfied)0
Baseline (dissatisfied)0
Baseline (very dissatisfied)0
Year 6 (very satisfied)279
Year 6 (somewhat satisfied)20
Year 6 (neither satisfied nor dissatisfied)3
Year 6 (dissatisfied)0
Year 6 (very dissatisfied)0
Year 7 (very satisfied)218
Year 7 (somewhat satisfied)20
Year 7 (neither satisfied nor dissatisfied)1
Year 7 (dissatisfied)3
Year 7 (very dissatisfied)1
Year 8 (very satisfied)207
Year 8 (somewhat satisfied)13
Year 8 (neither satisfied nor dissatisfied)3
Year 8 (dissatisfied)0
Year 8 (very dissatisfied)0

Adverse events

Collected over Years 6 to 8 of Mirena use. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levonorgestrel IUS (Mirena, BAY86-5028)0/362 (0%)14/362 (3.9%)107/362 (29.6%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventLevonorgestrel IUS (Mirena, BAY86-5028)
Uterine perforationInjury, poisoning and procedural complications3/362
Suicidal ideationPsychiatric disorders2/362
Iron deficiency anaemiaBlood and lymphatic system disorders1/362
VolvulusGastrointestinal disorders1/362
Tooth abscessInfections and infestations1/362
Urinary tract infectionInfections and infestations1/362
ObesityMetabolism and nutrition disorders1/362
Radial nerve palsyNervous system disorders1/362
Vertebral artery dissectionNervous system disorders1/362
Cerebellar strokeNervous system disorders1/362
Most frequent other events
Most frequent other events
EventLevonorgestrel IUS (Mirena, BAY86-5028)
Weight increasedInvestigations33/362
Bacterial vaginosisInfections and infestations27/362
Urinary tract infectionInfections and infestations27/362
NasopharyngitisInfections and infestations21/362
AnxietyPsychiatric disorders20/362

Baseline characteristics

FAS (full analysis set)

Age, Continuous
Age, Continuous(years)Levonorgestrel IUS (Mirena, BAY86-5028)
Mean29.4 ± 3.1
Sex: Female, Male
Sex: Female, Male(Participants)Levonorgestrel IUS (Mirena, BAY86-5028)
Female362
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Levonorgestrel IUS (Mirena, BAY86-5028)
Hispanic or Latino41
Not Hispanic or Latino319
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Levonorgestrel IUS (Mirena, BAY86-5028)
American Indian or Alaska Native2
Asian9
Native Hawaiian or Other Pacific Islander0
Black or African American51
White273
More than one race14
Unknown or Not Reported13
Parity
Parity(Participants)Levonorgestrel IUS (Mirena, BAY86-5028)
Nulliparous171
Parous191
08

Study locations

49 sites
  • Mobile, Alabama 36608-6703, United States
  • Phoenix, Arizona 85032, United States
  • Scottsdale, Arizona 85251, United States
  • Tucson, Arizona 85712, United States
  • Encinitas, California 92024, United States
  • San Francisco, California 94110, United States
  • Ventura, California 93003, United States
  • Aurora, Colorado 80045, United States
  • Atlanta, Georgia 30342, United States
  • Idaho Falls, Idaho 83404, United States
  • Fort Wayne, Indiana 46825, United States
  • Newburgh, Indiana 47630-8940, United States
  • Frederick, Maryland 21702, United States
  • Pikesville, Maryland 21208, United States
  • Boston, Massachusetts 02118, United States
  • Saginaw, Michigan 48604, United States
  • Lincoln, Nebraska 68510, United States
  • Las Vegas, Nevada 89106, United States
  • Lebanon, New Hampshire 03756-1000, United States
  • Lawrenceville, New Jersey 08648, United States
  • Neptune, New Jersey 07753, United States
  • Albuquerque, New Mexico 87109, United States
  • New York, New York 10032, United States
  • Port Jefferson, New York 11777, United States
  • Asheville, North Carolina 28801, United States
  • Durham, North Carolina 27713, United States
  • Greensboro, North Carolina 27408, United States
  • Hickory, North Carolina 28602, United States
  • Morehead City, North Carolina 28557, United States
  • New Bern, North Carolina 28562, United States
  • Winston-Salem, North Carolina 27103-1749, United States
  • Franklin, Ohio 45005-2593, United States
  • Mayfield Heights, Ohio 44124, United States
  • Portland, Oregon 97239, United States
  • Erie, Pennsylvania 16507, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Philadelphia, Pennsylvania 19107, United States
  • Chattanooga, Tennessee 37404, United States
  • Austin, Texas 78758, United States
  • Fort Worth, Texas 76104-4145, United States
  • Houston, Texas 77030, United States
  • Draper, Utah 84020-7163, United States
  • Midlothian, Virginia 23114, United States
  • North Chesterfield, Virginia 23235, United States
  • Roanoke, Virginia 24013-2256, United States
  • Virginia Beach, Virginia 23456, United States
  • Seattle, Washington 98105, United States
  • Seattle, Washington 98122, United States
  • Spokane, Washington 99207-1240, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in May 2021, 53 months.

Results were first posted in Apr 2022, 11 months after primary completion.

Of 17 phase 3 interventional studies under Menorrhagia, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 35. This study's 53 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2016
First posted
Dec 7, 2016
StartActual
Dec 22, 2016
Primary completionActual
May 28, 2021
CompletionActual
May 28, 2021
Results first posted
Apr 28, 2022
Last update
Apr 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02985541
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Dec 7, 2016
Start date
Dec 22, 2016
Primary completion
May 28, 2021
Completion
May 28, 2021
Results posted
Apr 28, 2022
Last update
Apr 28, 2022

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levonorgestrel

Start the discussion